The Pharmacokinetics of an oral uracil dose in patients with colorectal carcinoma.
Recruiting
- Conditions
- DPD deficiencyPharmacokineticscolorectalDPD deficiëntiekinetiekuracilcolorectaal
- Registration Number
- NL-OMON28016
- Lead Sponsor
- eveste Scheper ziekenhuisLeids Universitair medische CentumLeveste Scheper ZiekenhuisBoermarkeweg 607824 AA EmmenPostadresPostbus 30.0027800 RA Emmen
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 24
Inclusion Criteria
1. Age > 18 year;
2. Metastatic disease or adjuvant treatment;
Exclusion Criteria
1. DPD activity in PBMCs < 6 nmol/mg/hr;
2. Pregnancy;
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Compare the AUC of uracil in patients with metastatic colorectal disease and patients with adjuvant treatment.
- Secondary Outcome Measures
Name Time Method The second objective of the study is to determine if there is a interpatient correlation between uracil levels determined in blood sampled with a newly developed bloodspot mehthod and venapunction.AUC of uracil.<br>